New appointments for BioScience Managers

Latest News

BioScience Managers has announced the expansion of its team with the addition of three new directors - Dr Michael Perry, Dennis Purcell and Nicole Vitullo.

Dr Michael Perry was senior vice president and chief scientific officer for Novartis, having previously been chief scientific officer of their Cell and Gene Therapy Unit and global head of Cellular Therapy. He also previously served as a venture partner with Bay City Capital in San Francisco. In addition to his role with BioScience Managers, Dr Perry has taken on the helm as CEO of portfolio company, Avita Medical.

Dennis Purcell is a founder and former senior managing partner of Aisling Capital and remains a senior adviser to the company. He sits on numerous boards and has been honoured in the Biotech Hall of Fame by Genetic Engineering News and named on the Biotechnology All-Stars list by Forbes.

Nicole Vitullo is a partner with life sciences venture capital group Domain Associates LLC. She has extensive experience in public and private investment, and also liquidation strategies for public companies.

Jeremy Curnock Cook, managing director of BioScience Managers, said: “Michael, Dennis and Nicole bring a wealth of scientific, business and investment experience from a variety of senior roles, including as board members and executives with major pharmaceutical and bioscience companies.

“All have a global vision and detailed knowledge of what is required for a biomedical device, drug or innovation to be taken from discovery to successful commercialisation. 

“Our strategy is to deliver superior returns to our investors through our commitment to supporting our investee companies through development and growth to a level where they have achieved a significant increase in value. Our portfolio companies will benefit from the additional experience and international expertise in our senior team.”

The three new appointments join existing board members Jeremy Curnock Cook, Matt McNamara and Alan Cainey. 

Recently, to support its joint venture with Downing in the UK, BioScience Managers announced the appointment of London-based Elizabeth Klein, a senior research analyst with over 15 years life sciences sector experience.